1. Breast Cancer Drug Avastin Faces FDA Panel
... (Hellerman). Avastin's maker, Genentech, immediately filed an appeal before the FDA Commissioner Margaret Hamburg could finalize the decision. The law that created the "accelerated approval" process, which the drug was approved under, allowed for the appeal. Despite the ongoing battle, many doctors are already opting not to prescribe Avastin, according to Charlotte Arnold, a Genentech spokeswoman. Only 20- ... 25 percent of new breast cancer patients receive the drug, down from the former 60 percent before the panel voted (Hellerman). The accelerated approval program began in 1992 so pati...
- Word Count: 1317
- Approx Pages: 5
- Has Bibliography
- Grade Level: Undergraduate